Biotechnology
HanAll Biopharma Announces Results from Phase III randomized, double-masked active treatment-controlled VELOS-3 Trial Evaluating Tanfanercept 0.25% for Treatment of Dry Eye Disease
* Tanfanercept did not demonstrate statistical significance in either of the primary outcome measures of improvement in central corneal staining score (CCSS) or in improvement in Eye Dryness Score (EDS) assessed at week 8 in subjects with dry eye disease (DED), compared to vehicle. * However,...
2023-05-19 19:00
2741
ExoCoBio obtained a US Patent for Rose Stem Cell-derived Exosome (RSCE™)
- The first plant stem cell-derived exosome patent in the US - The 5th patent allowance following 3 in Korea and 1 in Japan - An important milestone for the global plant stem cell-derived exosome industry SEOUL, South Korea, May 19, 2023 /PRNewswire/ -- ExoCoBio, one of the top three exosome...
2023-05-19 16:34
7534
HitGen Announces Drug Discovery Research Agreement with ARase Therapeutics
CHENGDU, China, May 18, 2023 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH) announced today that it has entered into a research agreement with ARase Therapeutics, Inc. ("ARase"), a biotechnology company developing first-in-class therapeutics targetin...
2023-05-18 21:30
3288
Asieris Deepens Strategic Partnership with UroViu to Further Develop Integrated Diagnosis and Treatment Platform for Bladder Cancer
SHANGHAI, May 18, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced a strategic collaboration with UroViu C...
2023-05-18 16:00
2906
Antengene Announces Clearance of U.S. IND for the Phase I Trial of First-in-Class Anti-CD24 Monoclonal Antibody ATG-031
- ATG-031, discovered and developed in-house by Antengene, is the world's first anti-CD24 antibody to advance to the clinic in oncologyand Antengene's third drug candidate to enter clinical studies in the U.S. - The Phase I "PERFORM" study will evaluate the safety and tolerability, pharmacolog...
2023-05-18 02:47
3493
Skyline Therapeutics Brings Multiple Data Presentations to ASGCT 2023
SHANGHAI, May 17, 2023 /PRNewswire/ -- Skyline Therapeutics, an innovation-driven gene therapy company dedicated to developing unique and novel solutions to address unmet needs in rare and severe diseases, is showcasing multiple data presentations at the American Society of Gene and Cell Therapy ...
2023-05-17 18:00
2774
Fresh2 Files Annual Report on Form 20-F for Fiscal Year 2022
NEW YORK, May 16, 2023 /PRNewswire/ -- Fresh2 Group Limited (Formerly AnPac Bio-Medical Science Co., Ltd., "Fresh2," the "Company" or "we") (NASDAQ: ANPC), a company with operations inthe United States and China focused on early cancer screening and detection and entering into the operation of a ...
2023-05-17 05:00
3985
Fresh2 Reports Fiscal Year 2022 Annual Financial Results
NEW YORK, May 16, 2023 /PRNewswire/ -- Fresh2 Group Limited (Formerly AnPac Bio-Medical Science Co., Ltd. ,"Fresh2," the "Company" or "we") (NASDAQ: ANPC), a company with operations inthe United States and China focused on early cancer screening and detection and entering into the operation of a ...
2023-05-17 04:15
3187
Eluminex Biosciences Receives Scientific Recognition for its Recombinant Human Collagen (rhCIII) Biosynthetic Cornea (EB-301) Program to Treat Corneal Blindness
Awarded Honors at the American Society of Cataract and Refractive Surgery (ASCRS) andthe Association for Research in Vision and Ophthalmology (ARVO) SUZHOU, China and SAN FRANCISCO, May 16, 2023 /PRNewswire/ -- Eluminex Biosciences (Eluminex) announced that its clinical pivotal study (CLARITY) e...
2023-05-16 23:00
2690
The first spring CMEF exhibition after the COVID-19 pandemic in the Chinese mainland: A brief discussion on the rise and challenges of China's domestic medical apparatus from Diagens Biotechnology
SHANGHAI, May 16, 2023 /PRNewswire/ -- From May 14th to 17th, 2023, a global medical technology event kicked off inChina. The 87th China International Medical Equipment (Spring)Fair (CMEF) attracted industry elites from more than 20 countries and regions around the world under the theme of "Innov...
2023-05-16 21:39
2909
WuXi Biologics Announces Manufacturing Partnership with InflaRx to Advance Gohibic for the Treatment of Certain Critically Ill COVID-19 patients
* WuXi Biologics is the manufacturing partner of InflaRx for Gohibic (vilobelimab), a first-in-class monoclonal anti-C5a antibody. * InflaRx received emergency use authorization (EUA) from the FDA for Gohibic (vilobelimab) for the treatment of certain critically ill COVID-19 patients in April ...
2023-05-16 16:00
2716
ChomiX Biotech Announces millions of dollars Series Pre-A+ Financing to accelerate the development of Chemoproteomics Platform
NANJING, China, May 15, 2023 /PRNewswire/ -- Recently, ChomiX Biotech Co., Ltd. (hereinafter referred to as ChomiX), a leading biotechnology company focusing on the preclinical development of innovative small molecule drugs, announced the completion of millions of dollars Pre-A+ Financing by Tige...
2023-05-15 20:00
2573
Gracell Biotechnologies Initiates Investigational Study Evaluating GC012F for Treatment of Refractory Systemic Lupus Erythematosus (SLE)
Gracell announces start of investigator-initiated trial to expand clinical evaluation of FasTCAR-T GC012F into autoimmune disease GC012F pioneers the use of CD19/BCMA dual-targeting CAR-T in SLE, aiming for deeper and wider depletion of autoantibodies producing B-cells and plasma cells SAN DIEGO...
2023-05-15 19:00
2962
LaNova Medicines Announces Global Exclusive License Agreement with AstraZeneca for LM-305, a Novel GPRC5D-Targeting Antibody Drug Conjugate
SHANGHAI, May 12, 2023 /PRNewswire/ -- LaNova Medicines Ltd. ("LaNova Medicines") announced today it has entered into an exclusive license agreement with AstraZeneca (LSE/STO/Nasdaq: AZN), for LM-305, a pre-clinical stage antibody drug conjugate (ADC) targeting G protein-coupled receptor, class C...
2023-05-12 23:30
4763
Crystal Formulation Services' GMP Manufacturing Facility Successfully Passes the Remote Audit by US Client, Marking a Key Milestone for Its International Expansion
SUZHOU, China, May 12, 2023 /PRNewswire/ -- Today, Crystal Pharmatech announced that the GMP manufacturing facility of their CDMO business unit – Crystal Formulation Services (CFS) has successfully passed a remote audit conducted by a US client. The audit, which lasted for four days, confirmed th...
2023-05-12 21:00
3132
Nona Biosciences Announces Strategic Collaboration Agreement with PharmaEssentia Innovation Research Center
CAMBRIDGE, Mass., May 11, 2023 /PRNewswire/ -- Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited, committed to cutting-edge technology innovation and provider of integrated solutions from "Idea to IND" (I to I™), announced today it has entered into a strategic collaboration agre...
2023-05-12 09:32
2941
Gracell Biotechnologies to Present Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in RRMM and B-NHL and Donor-Derived CAR-T GC007g in B-ALL at EHA2023 Congress
First disclosure of data from Phase 1 study of the donor-derived allogeneic CAR-T GC007g shows 100% overall response rate (ORR) and a favorable safety profile for treatment ofrelapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) Longer-term GC012F data in relapsed/refractory multip...
2023-05-12 05:28
3352
NewFish partners with Socius Ingredients to develop algae proteins for USA sports and active nutrition market
CHICAGO, May 11, 2023 /PRNewswire/ -- NewFish has entered into a co-development partnership agreement withChicago-based Socius Ingredients to commercialise microalgae proteins and specialized ingredients targeting the active nutrition market in theUSA. The active and sports nutrition market in t...
2023-05-12 03:52
2237
CytoMed Therapeutics to Ring Nasdaq Closing Bell
SINGAPORE, May 11, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited ("CytoMed" or the "Company") (Nasdaq: GDTC), a biopharmaceutical company focused on harnessing its licensed proprietary technologies to create novel allogeneic cell-based immunotherapies for the treatment of human cancers, will ...
2023-05-11 21:00
4539
Lunit to Present 16 Abstracts at the 2023 ASCO Annual Meeting
- Lunit and collaborators demonstrate the predictive value and analytical prowess of Lunit's AI-biomarker platform in a wide range of cancer types and clinical practices SEOUL, South Korea, May 10, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading global provider of AI-powered cancer di...
2023-05-10 13:44
3240
Week's Top Stories
Most Reposted
TotalEnergies ENEOS Extends Solar Partnership with Ceres in Indonesia
[Picked up by 316 media titles]
2026-06-08 10:16
DayOne Secures Over 1GW Renewable Energy in Malaysia in Landmark TNB Partnership
[Picked up by 303 media titles]
2026-06-04 23:55
Amartha Initiates Coalition to Advance Financial Health for Grassroots Communities in Indonesia
[Picked up by 296 media titles]
2026-06-05 19:08
DayOne Data Centers Announces Final Closing of its Series C Equity Financing at US$4.5 Billion
[Picked up by 294 media titles]
2026-06-05 15:00Omni HR Launches Mino, the First AI Agent Built on Unified APAC HR Data
[Picked up by 283 media titles]
2026-06-08 09:00
Most Read
YY Group (NASDAQ: YYGH) Wins Prestigious HAPA Solutions Excellence Award, Validating Enterprise AI Marketplace Adoption in Southeast Asia
2026-06-05 19:37
8472
Dreame ranked No.1 in Global Robot Vacuum Sales & Revenue, according to International Data Corporation (IDC)
2026-06-05 21:05
8061
Eratrectinib, the next-generation TRK inhibitor independently developed by Vcare PharmaTech, has received marketing approval
2026-06-05 22:00
7546
CERAVE CELEBRATES OVER 100 AWARD-WINNING CONTENT CREATORS FROM 22 COUNTRIES FOR THE FIRST EVER GLOBAL CERAWARDS
2026-06-05 20:58
7400
Tuniu Announces Unaudited First Quarter 2026 Financial Results
2026-06-05 18:00
7323